1. 539PProfiling of immune related adverse events from nivolumab or pembrolizumab monotherapy in advanced non-small cell lung cancer in real world. (25th November 2018) Authors: Aso, M; Sugawara, S; Toi, Y; Sugisaka, J; Ono, H; Tsurumi, K; Suzuki, K; Shimizu, H; Domeki, Y; Aiba, T; Kawana, S; Saito, R; Terayama, K; Kawashima, Y; Nakamura, A; Yamanda, S; Kimura, Y; Honda, Y Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗